Age or Disability Should Not Prevent Access to Care
- The Institute for Clinical and Economic Review (ICER) produces reports, known as “cost effectiveness analyses” or “value assessments” on how much it thinks new drugs should cost.
- ICER metrics value treating young individuals in good health as more cost-effective than treating older adults (65 and older) or people with disabilities.
- Insurance companies use these values to decide whether it’s worth paying for a certain treatment or test.
- Sick and older patients are more likely to be denied access to medications that could help improve their condition or quality of life.
It is time for patients to say “enough is enough” and stand against discrimination in healthcare. Sign up today to receive news updates on ICER’s activity and opportunities to connect with elected officials on the importance of protecting patients’ rights.